在撒哈拉以南非洲，多替拉韦的依从性、耐药性和病毒抑制：对 TLD 时代的影响。
Adherence, resistance, and viral suppression on dolutegravir in sub-Saharan Africa: implications for the TLD era.
机构信息
Medical Practice Evaluation Center.
Division of Infectious Diseases, Massachusetts General Hospital.
出版信息
AIDS. 2021 Dec 15;35(Suppl 2):S127-S135. doi: 10.1097/QAD.0000000000003082.
Abstract
Dolutegravir (DTG) is now a component of preferred first-line antiretroviral therapy (ART) worldwide. ADVANCE and NAMSAL were two landmark clinical trials conducted exclusively in sub-Saharan Africa, which studied the effectiveness of DTG-based first-line regimens for ART-naive individuals. In this review, we examine the data from these studies to consider the contributions of adherence and HIV drug resistance to treatment failure on DTG-based ART, as compared with efavirenz (EFV)-based ART, which has a lower genetic barrier to resistance. We also discuss the implications of virologic failure on DTG and consolidate currently available data to conclude with recommendations for virologic monitoring on DTG-based ART.
摘要
多替拉韦（DTG）现已成为全球首选一线抗逆转录病毒治疗（ART）的组成部分。ADVANCE 和 NAMSAL 是两项专门在撒哈拉以南非洲进行的具有里程碑意义的临床试验，研究了 DTG 为基础的一线方案在初治人群中的有效性。在这篇综述中，我们研究了这些研究的数据，以考虑依从性和 HIV 耐药性对基于 DTG 的 ART 治疗失败的贡献，与具有较低遗传耐药屏障的依非韦伦（EFV）为基础的 ART 相比。我们还讨论了 DTG 病毒学失败的影响，并整合了目前可用的数据，得出了关于 DTG 为基础的 ART 病毒学监测的建议。
相似文献
1
Adherence, resistance, and viral suppression on dolutegravir in sub-Saharan Africa: implications for the TLD era.在撒哈拉以南非洲，多替拉韦的依从性、耐药性和病毒抑制：对 TLD 时代的影响。
AIDS. 2021 Dec 15;35(Suppl 2):S127-S135. doi: 10.1097/QAD.0000000000003082.
2
Virologic outcomes on dolutegravir-, atazanavir-, or efavirenz-based ART in urban Zimbabwe: A longitudinal study.津巴布韦城市中基于多替拉韦、阿扎那韦或依非韦伦的 ART 的病毒学结局：一项纵向研究。
PLoS One. 2024 Feb 23;19(2):e0293162. doi: 10.1371/journal.pone.0293162. eCollection 2024.
3
Comparative efficacy, safety and durability of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: an update on a systematic review and network meta-analysis.在初治 HIV-1 感染者中，与常见核心药物相比，多替拉韦的疗效、安全性和持久性：系统评价和网络荟萃分析的更新。
BMC Infect Dis. 2021 Feb 26;21(1):222. doi: 10.1186/s12879-021-05850-0.
4
Doing More With Less: Review of Dolutegravir-Lamivudine, a Novel Single-Tablet Regimen for Antiretroviral-Naïve Adults With HIV-1 Infection.少即是多：多替拉韦/拉米夫定片治疗初治 HIV-1 感染成人的疗效评价。
Ann Pharmacother. 2020 Dec;54(12):1252-1259. doi: 10.1177/1060028020933772. Epub 2020 Jun 9.
5
Challenges of scale-up to dolutegravir-based regimens in sub-Saharan Africa.在撒哈拉以南非洲地区将基于多替拉韦的方案扩大规模所面临的挑战。
AIDS. 2020 Apr 1;34(5):783-787. doi: 10.1097/QAD.0000000000002470.
6
First case of Dolutegravir and Darunavir/r multi drug-resistant HIV-1 in Cameroon following exposure to Raltegravir: lessons and implications in the era of transition to Dolutegravir-based regimens.喀麦隆首例拉替拉韦暴露后多药物耐药 HIV-1 型病毒（达芦那韦/利托那韦）：在向基于多替拉韦方案过渡时代的经验与启示。
Antimicrob Resist Infect Control. 2020 Aug 26;9(1):143. doi: 10.1186/s13756-020-00799-2.
7
Impact of scaling up dolutegravir on antiretroviral resistance in South Africa: A modeling study.扩大度鲁特韦在南非抗逆转录病毒耐药性方面的影响：一项建模研究。
PLoS Med. 2020 Dec 14;17(12):e1003397. doi: 10.1371/journal.pmed.1003397. eCollection 2020 Dec.
8
Mother-to-Child HIV Transmission With In Utero Dolutegravir vs. Efavirenz in Botswana.博茨瓦纳在体 dolutegravir 与依非韦伦治疗母婴 HIV 传播的比较。
J Acquir Immune Defic Syndr. 2020 Jul 1;84(3):235-241. doi: 10.1097/QAI.0000000000002338.
9
The association between adherence to antiretroviral therapy and viral suppression under dolutegravir-based regimens: an observational cohort study from Uganda.基于多替拉韦方案的抗逆转录病毒治疗依从性与病毒抑制之间的关联：来自乌干达的一项观察性队列研究。
J Int AIDS Soc. 2024 Aug;27(8):e26350. doi: 10.1002/jia2.26350.
10
Dolutegravir response in antiretroviral therapy naïve and experienced patients with M184V/I: Impact in low-and middle-income settings.初治和经治 HIV 感染者中 M184V/I 对多替拉韦的反应：中低收入国家的影响。
Int J Infect Dis. 2021 Apr;105:298-303. doi: 10.1016/j.ijid.2021.03.018. Epub 2021 Mar 16.
引用本文的文献
1
Approaches to the Management of Virologic Failure on Dolutegravir-Based Antiretroviral Therapy in the 50 Countries with the Highest Adult HIV Prevalence.在成人艾滋病毒感染率最高的50个国家中，基于多替拉韦的抗逆转录病毒疗法治疗病毒学失败的管理方法。
Clin Infect Dis. 2025 Aug 11. doi: 10.1093/cid/ciaf444.
2
Factors Associated with Incomplete Adherence to Dolutegravir-Based Antiretroviral Therapy in Southwestern Uganda.乌干达西南部与基于多替拉韦的抗逆转录病毒疗法依从性不完全相关的因素
J Acquir Immune Defic Syndr. 2025 Aug 4. doi: 10.1097/QAI.0000000000003735.
3
Patients reported neuropsychiatric adverse events and associated factors among PLHIV patients receiving DTG-based regimen antiretroviral therapy real-life clinical practice in Ethiopia: multi center crossetional study.在埃塞俄比亚接受基于多替拉韦（DTG）方案抗逆转录病毒治疗的真实临床实践中，HIV感染者报告的神经精神不良事件及相关因素：多中心横断面研究
BMC Psychiatry. 2025 Apr 16;25(1):383. doi: 10.1186/s12888-025-06820-5.
4
HIV-1 Antiretroviral Drug Resistance in Mozambique: A Systematic Review and Meta-Analysis.莫桑比克的HIV-1抗逆转录病毒药物耐药性：一项系统评价与荟萃分析
Viruses. 2024 Nov 21;16(12):1808. doi: 10.3390/v16121808.
5
Brief communication: Long-term treatment outcomes of transitioning to dolutegravir-based ART from efavirenz in HIV study participants in Mbeya, Tanzania.简短通讯：坦桑尼亚姆贝亚地区HIV研究参与者从依非韦伦转换为基于多替拉韦的抗逆转录病毒治疗的长期治疗结果
AIDS Res Ther. 2024 Dec 23;21(1):98. doi: 10.1186/s12981-024-00662-z.
6
Viral suppression and adherence in adolescents living with HIV in rural Tanzania.坦桑尼亚农村地区感染艾滋病毒青少年的病毒抑制情况及依从性
PLoS One. 2024 Dec 20;19(12):e0315866. doi: 10.1371/journal.pone.0315866. eCollection 2024.
7
Factors associated with self-reported suboptimal antiretroviral adherence and limited retention in care among people living with HIV who attend a large ART clinic in Panama City, Panama.与巴拿马城一家大型抗逆转录病毒治疗诊所中接受治疗的艾滋病毒感染者自我报告的抗逆转录病毒药物依从性差和保留在治疗中的人数有限相关的因素。
PLoS One. 2024 Nov 27;19(11):e0311048. doi: 10.1371/journal.pone.0311048. eCollection 2024.
8
Patterns of HIV-1 Drug Resistance Observed Through Geospatial Analysis of Routine Diagnostic Testing in KwaZulu-Natal, South Africa.南非夸祖鲁-纳塔尔省常规诊断检测的地理空间分析观察到的 HIV-1 耐药模式。
Viruses. 2024 Oct 19;16(10):1634. doi: 10.3390/v16101634.
9
Viral load suppression and HIV-1 drug resistance mutations in persons with HIV on TLD/TAFED in Zambia.赞比亚 TLD/TAFED 方案治疗的 HIV 感染者的病毒载量抑制和 HIV-1 耐药突变。
PLoS One. 2024 Sep 6;19(9):e0308869. doi: 10.1371/journal.pone.0308869. eCollection 2024.
10
The association between adherence to antiretroviral therapy and viral suppression under dolutegravir-based regimens: an observational cohort study from Uganda.基于多替拉韦方案的抗逆转录病毒治疗依从性与病毒抑制之间的关联：来自乌干达的一项观察性队列研究。
J Int AIDS Soc. 2024 Aug;27(8):e26350. doi: 10.1002/jia2.26350.
Zotero 插件